Clinical AI evaluation must go beyond benchmark wins | Wolters Kluwer
PushButton AI Team ·
Clinical AI evaluation must go beyond benchmark wins | Wolters Kluwer
Everyone's chasing AI tools that score well on paper. But scoring well on paper isn't the same as working in your business.
That $200/month tool collecting dust? It probably looked great in the demo.
Everyone's chasing AI tools that score well on paper. But scoring well on paper isn't the same as working in your business.
That $200/month tool collecting dust? It probably looked great in the demo. Most do. You're not foolish for buying it — you were sold a benchmark, not a real-world solution.
Here's what clinical AI researchers recently confirmed (and it applies directly to your business): a tool that wins in controlled testing can still fail completely when real people use it in real workflows. The gap between "impressive demo" and "actual daily use" is where most AI investments die.
The lesson isn't to distrust AI. It's to change your evaluation criteria. Stop asking "Is this AI powerful?" Start asking "Will my team actually open this tomorrow morning, and does it slot into how we already work?"
Before your next AI decision, run a two-week live test with one real employee on one real task. No full rollout. No big commitment. Just observe whether they use it voluntarily after day three. If they don't, the tool failed — not your team.
That single test has saved my clients from some very expensive mistakes.
What's the biggest gap you've seen between what an AI tool promised and what it actually delivered?
